Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Despite Lack of Specific Expertise, Doctors May Testify on Causation
In a 34-page opinion in Wolfe v. McNeil-PPC Inc., U.S. District Judge Jan E. DuBois held that a doctor testifying as an expert witness may opine as to causation using a “differential diagnosis” ' in other words, he or she is permitted to testify that, because other causes have been ruled out, the pharmaceutical product at issue likely caused the condition. The case involves a child who was given ibuprofen, after which she developed Stevens-Johnson Syndrome (SJS), a life-threatening condition in which the epidermis separates from the dermis. The plaintiffs assert that the warning label for Children's Motrin, which contained the ibuprofen, was inadequate. Plaintiffs are also seeking punitive damages, claiming that the drug's manufacturer withheld evidence from the FDA showing that two previous users had developed SJS. The defense objected to the plaintiffs' proffer of testimony from three doctors, none of whom is an expert in or has studied the causes of SJS. In rebuffing the objections, Judge DuBois concluded that the U.S. Supreme Court's 1991 decision in Daubert v. Merrell Dow Pharmaceuticals Inc. does not require an expert's knowledge base to be as specialized as the defense urged. Experts need not be “the best qualified” or “have the specialization that the court considers most appropriate,” wrote Justice DuBois. An expert's deficiencies in knowledge, if any, go to the questions of credibility and weight, concluded the judge, not admissibility.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.
Each stage of an attorney's career offers opportunities for a curriculum that addresses both the individual's and the firm's need to drive success.
A defendant in a patent infringement suit may, during discovery and prior to a <i>Markman</i> hearing, compel the plaintiff to produce claim charts, claim constructions, and element-by-element infringement analyses.